Immuneering Corp (NASDAQ: IMRX) – Suitable For Long Term Buy?
Currently, there are 35.99M common shares owned by the public and among those 25.96M shares have been available to trade. The company’s stock has a 5-day price change of -16.13% and 8.33% over the past three months. IMRX shares are trading -17.27% year to date (YTD), with the 12-month market performance up to 7.69% higher. […]